Each spray is structured to deliver 50MCG Dihexa, 50MCG Semax, and 50MCG Selank for controlled laboratory research models
In 2021, a new era in obesity pharmacotherapy was established with the FDA approval of semaglutide, a high-dose glucagon-like-peptide-1 receptor (GLP-1R) agonist which causes about a 12% placebo-subtracted weight loss in people with obesity at 68 weeks of treatment (5)
Non-diabetic patients actually avoid hypoglycemia risks that diabetic users face, though they still require medical supervision for dose adjustment and side effect management
EMA medicine record European Medicines Agency
The main safety risk comes from unregulated sourcing
Activating sirtuins through adequate NAD+ levels is associated with improved mitochondrial function, reduced inflammation, and extended cellular lifespan